Gilead and Merck share data from phase 2 trial of HIV treatment
Betsy Goodfellow | March 7, 2024 | News story | Research and Development | Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 clinical study assessing the combination of islatravir and lenacapavir for viral suppression in HIV treatment.
The results were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI), and demonstrated that at 24 weeks the investigational combination maintained a 94.2% rate of viral suppression (HIV-1 RNA <50 copies/mL), which was a secondary endpoint on the trial.
Following this data around the antiviral activities, as well as the pharmacokinetics profiles of the two drugs, it is expected that the development of this combination will continue.
Jared Baeten MD PhD, vice president, HIV clinical development at Gilead Sciences, commented: “HIV treatment is not one size fits all – developing once-weekly treatment options could help meet the needs of each individual, aiming toward maximising long-term outcomes for people with HIV. This promising data presented at CROI helps bring us one step closer to our goal of providing a wide range of options that may help transform the HIV treatment landscape.”
Dr Elizabeth Rhee, vice president, global clinical development at Merck Research Laboratories, added: “Our strategies for managing and treating HIV must evolve with the needs of the HIV community, and we are excited to have this promising first data from the phase 2 study for islatravir and lenacapavir presented at CROI. Gilead and Merck remain committed to this collaboration and to the development of a potential once-weekly oral therapy for people living with HIV who may need additional options to help maintain viral suppression.”
Betsy Goodfellow
Related Content
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
